RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US

Detalles Bibliográficos
Autores principales: Kukreja, I, Gaur, A, Upadhyay, N, Bhalani, S, Gupta, A, Verma, V, Pandey, S, Roy, A, Nayyar, A, Daral, S, Chawla, S, Mohanty, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747462/
http://dx.doi.org/10.1016/j.jval.2022.09.2354
_version_ 1784849604576018432
author Kukreja, I
Gaur, A
Upadhyay, N
Bhalani, S
Gupta, A
Verma, V
Pandey, S
Roy, A
Nayyar, A
Daral, S
Chawla, S
Mohanty, P
author_facet Kukreja, I
Gaur, A
Upadhyay, N
Bhalani, S
Gupta, A
Verma, V
Pandey, S
Roy, A
Nayyar, A
Daral, S
Chawla, S
Mohanty, P
author_sort Kukreja, I
collection PubMed
description
format Online
Article
Text
id pubmed-9747462
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-97474622022-12-14 RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US Kukreja, I Gaur, A Upadhyay, N Bhalani, S Gupta, A Verma, V Pandey, S Roy, A Nayyar, A Daral, S Chawla, S Mohanty, P Value Health Article Published by Elsevier Inc. 2022-12 2022-12-14 /pmc/articles/PMC9747462/ http://dx.doi.org/10.1016/j.jval.2022.09.2354 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kukreja, I
Gaur, A
Upadhyay, N
Bhalani, S
Gupta, A
Verma, V
Pandey, S
Roy, A
Nayyar, A
Daral, S
Chawla, S
Mohanty, P
RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US
title RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US
title_full RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US
title_fullStr RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US
title_full_unstemmed RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US
title_short RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US
title_sort rwd129 a comparison of icu admission rate and related cost among patients taking nirmatrelvir and ritonavir combination versus molnupiravir for treatment of mild to moderate covid-19 in the us
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747462/
http://dx.doi.org/10.1016/j.jval.2022.09.2354
work_keys_str_mv AT kukrejai rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT gaura rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT upadhyayn rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT bhalanis rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT guptaa rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT vermav rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT pandeys rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT roya rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT nayyara rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT darals rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT chawlas rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus
AT mohantyp rwd129acomparisonoficuadmissionrateandrelatedcostamongpatientstakingnirmatrelvirandritonavircombinationversusmolnupiravirfortreatmentofmildtomoderatecovid19intheus

Ejemplares similares